Efficacy and Safety of Drug Elution Bead-Transarterial Chemoembolization in Advanced Soft Tissue Sarcoma
DOI:
https://doi.org/10.35790/msj.v7i2.58794Abstract
Abstract: Soft-tissue sarcomas (STS) are rare and heterogeneous tumors originating from mesenchymal tissues. While surgical resection remains the primary treatment, not all patients are eligible for surgery, particularly in advanced stages. Drug-eluting bead transarterial chemoemboli zation (DEB-TACE) is a promising therapeutic option for such cases. This retrospective study evaluated the efficacy and safety of DEB-TACE in 30 patients with advanced STS at Prof. Dr. R. D. Kandou Hospital, Manado, from 2020 to 2023. The overall response rate (ORR) was 76.7% (p<0.05), with five patients achieving complete response and 18 showing partial response. The main adverse reactions included post-embolization syndrome (fever, pain, nausea, vomiting) and grade II or higher bone marrow suppression. Despite a morbidity rate of 93.3%, no treatment-related mortality was observed. In conclusion, DEB-TACE is an effective and safe treatment for advanced STS, providing superior short-term efficacy compared to traditional systemic chemotherapy.
Keywords: soft tissue sarcoma; drug eluting bead; transarterial chemoembolization
References
Burns J, Wilding CP, Krasny L, Zhu X, Chadha M, Tam YB, et al. The proteomic landscape of soft tissue sarcomas. Nature Communications. 2023;14(1):3834. Doi: https://doi.org/10.1038/s41467-023-39486-2
Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies. Nat Rev Clin Oncol. 2014;11(4):187-202. Doi:10.1038/nrclinonc.2014.26
Osoro I, Sharma A, Amir M, Vohra M, Kumar R, Kumar H, et al. Prevention and management of anthracycline induced cardiotoxicity: a review. Health Sciences Review. 2022;5:100070. Available from: https://doi.org/10.1016/j.hsr.2022.100070
Larijani SR, Ravari SN, Goodarzi N, Akhlaghpour S, Larijani SS, Rouini MR, et al. Current status of transarterial chemoembolization (TACE) agents in hepatocellular carcinoma treatment. J Drug Deliv Sci Technol. 2022;77:103905. Available from: https://doi.org/10.1016/j.jddst.2022.103905
Schindler P, Kaldewey D, Rennebaum F, Trebicka J, Pascher A, Wildgruber M, et al. Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis. J Cancer Res Clin Oncol. 2024;150(5): 235. Available from: https://doi.org/10.1007/s00432-024-05722-5
Filho DWJ, Uchiyama AAT, Marchon C, Lopes LMD, de Castro Baccarin AL, de Fina B, et al. A Successful chemoembolization of a retroperitoneal soft tissue sarcoma: a case report. Case Rep Oncol. 2021; 14(3):1691-7. Doi:10.1159/000520381
Tam KY, Leung KC-F, Wang Y-XJ. Chemoembolization agents for cancer treatment. European Journal of Pharmaceutical Sciences. 2011;44(1):1-10. Availble from: https://doi.org/10.1016/j.ejps.2011.06.013
Burrel M, Bermúdez P. Drug-Eluting Embolic TACE (DEB-TACE). In: Lucatelli P, editor. Transarterial Chemoembolization (TACE). Cham: Springer International Publishing; 2023. p. 57-64. Available from: https://doi.org/10.1007/978-3-031-36261-3_7
Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, et al. DEB-TACE: a standard review. Future Oncol. 2018;14(28):2969-84. Doi: 10.2217/fon-2018-0136.
Al-Khazraji Y, Muzammil MA, Javid S, Tangella AV, Gohil NV, Saifullah H, et al. Novel regimens and treatment strategies in neoadjuvant therapy for colorectal cancer: a systematic review. Int J Health Sci (Qassim). 2024;18(5):43-58. Available from: https://pubmed.ncbi.nlm.nih.gov/39282125/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Albert Albert, Christian O. Manginstar, Denny saleh, Marselus A. Merung
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
